렘데시비르는 당초 에볼라 치료제로 개발됐지만 코로나19 입원 환자를 대상으로 한 임상시험에서 긍정적 결과가 나와 주목을 받고 있다.
Remdesivir was initially developed as a treatment for Ebola, but it is attracting attention with positive results in clinical trials involving patients of COVID-9 in hospital.